Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

A number of other brokerages have also issued reports on CTLT. Stephens reaffirmed an equal weight rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. UBS Group reaffirmed a neutral rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Royal Bank of Canada reaffirmed a sector perform rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Finally, Barclays boosted their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a research report on Thursday, January 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of Hold and a consensus price target of $52.46.

Catalent Stock Performance

NYSE:CTLT opened at $55.92 on Friday. Catalent has a 12 month low of $31.45 and a 12 month high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company’s 50 day moving average is $56.68 and its 200-day moving average is $48.70.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the firm posted $0.62 EPS. The company’s revenue was down 10.2% compared to the same quarter last year. On average, equities research analysts predict that Catalent will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Catalent

Several institutional investors and hedge funds have recently made changes to their positions in the company. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Czech National Bank boosted its stake in shares of Catalent by 0.7% in the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. BNP Paribas Asset Management Holding S.A. boosted its stake in shares of Catalent by 1.9% in the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after purchasing an additional 328 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Catalent by 6.2% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after purchasing an additional 331 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Catalent by 2.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock valued at $636,000 after purchasing an additional 350 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.